MergerMay 19, 2026, 10:41 AM
InMed & Mentari Announce Merger; US$290M Private Placement
AI Summary
InMed Pharmaceuticals Inc. announced a definitive merger agreement with Mentari Therapeutics, Inc., an all-stock transaction aimed at advancing migraine prevention therapies. The merger is coupled with an oversubscribed US$290 million private placement for Mentari, expected to fund the combined company's operations through 2028. Upon closing, pre-merger Mentari stockholders will own approximately 98.49% of the combined entity, which will operate as Mentari Therapeutics and trade on Nasdaq under a new ticker symbol. The transaction, valued at a pro forma equity of approximately US$421.4 million, is anticipated to close in the second half of 2026, pending shareholder and regulatory approvals.
Key Highlights
- InMed Pharmaceuticals and Mentari Therapeutics entered a definitive merger agreement.
- Pre-merger Mentari stockholders will own approximately 98.49% of the combined company.
- Pre-merger InMed shareholders will own approximately 1.51% of the combined company.
- Concurrent oversubscribed private placement of US$290 million for Mentari.
- Combined company's pro forma equity value is approximately US$421.4 million.
- Funding expected to cover operations through 2028, beyond key clinical data points.
- MT-001 Phase 2a proof-of-concept data expected in 2028.
- MT-002 Phase 1 healthy volunteer data expected in 2027.
- Merger expected to close in the second half of 2026, subject to shareholder approvals.
Price Impact
More from INM